Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors.

Next Previous
X
Search
Trial Profile

Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belinostat (Primary)
  • Indications Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors TopoTarget

    • Most Recent Events

    • 11 Nov 2011 Interim results will be presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH-2011).
    • 28 Apr 2011 Planned end date changed from 1 Dec 2010 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 28 Apr 2011 Planned end date changed from 1 Dec 2010 to 1 May 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top